« Back
Home /
GSK256066

GSK256066

Item no.	M1728-200mg
Manufacturer	AbMole
CASRN	801312-28-7
Amount	200mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	0,9853
Citations	In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. Nials, et al . J Pharmacol Exp Ther. 2011 Apr,337(1):137-44. PMID: 21205924 . GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. Tralau-Stewart, et al . J Pharmacol Exp Ther. 2011 Apr,337(1):145-54. PMID: 21205923 . The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Singh, et al . Respir Res. 2010 Mar 1,11:26. PMID: 20193079 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Similar products	GSK256066
Available
Target Information	PDE
Molecular Weight	518, 58
Solubility	DMSO 5 mg/mL
Bioactivity information	GSK256066 is a selective phosphodiesterase 4 (PDE4)inhibitor with an IC50 of 3.2 pM. *The compound is unstable in solutions, freshly prepared is recommended

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1728-200mg-safety-datasheet.pdf